Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer

Currently, pancreatic cancer remains one of the most unfavorable tumor pathologies, characterized by pronounced difficulties in diagnostics and treatment, a significant impact on the ability to work and quality of life of patients, and low indicators of patient life expectancy. Features of the devel...

Full description

Saved in:
Bibliographic Details
Main Authors: L. I. Moskvicheva, L. V. Bolotina
Format: Article
Language:Russian
Published: QUASAR, LLC 2020-12-01
Series:Исследования и практика в медицине
Subjects:
Online Access:https://www.rpmj.ru/rpmj/article/view/637
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568673835941888
author L. I. Moskvicheva
L. V. Bolotina
author_facet L. I. Moskvicheva
L. V. Bolotina
author_sort L. I. Moskvicheva
collection DOAJ
description Currently, pancreatic cancer remains one of the most unfavorable tumor pathologies, characterized by pronounced difficulties in diagnostics and treatment, a significant impact on the ability to work and quality of life of patients, and low indicators of patient life expectancy. Features of the development of malignant neoplasms of this localization contribute to limiting the possibility of performing radical surgery, and therefore a special role in the treatment of patients with pancreatic cancer is assigned to chemotherapy. Specific systemic drug therapy for this pathology is the most important and, in the majority of cases, mandatory element of treatment. It can be carried out in a neoadjuvant, adjuvant and independent mode, include mono- or multi- component schemes, and be combined with other types of systemic or local antitumor effects. The choice of chemotherapy regimen depends primarily on the General somatic status of the patient and is determined by the potential toxicity of a particular combination of cytostatics. This review of the literature demonstrates the effectiveness of various chemotherapy regimens in patients with stage III–IV pancreatic cancer in the first and second lines, describes the frequency of adverse reactions to treatment and their nature, and mentions ways to reduce the toxicity of multicomponent drug therapy regimens. This review is based on the analysis of scientific sources of the Internet resource "National Center for Biotechnological Information".
format Article
id doaj-art-e435fed625a54612a0f1196daf9dc7e0
institution Kabale University
issn 2410-1893
language Russian
publishDate 2020-12-01
publisher QUASAR, LLC
record_format Article
series Исследования и практика в медицине
spelling doaj-art-e435fed625a54612a0f1196daf9dc7e02025-02-03T00:57:37ZrusQUASAR, LLCИсследования и практика в медицине2410-18932020-12-017411813410.17709/2409-2231-2020-7-4-10358Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancerL. I. Moskvicheva0L. V. Bolotina1P.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological CentreP.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological CentreCurrently, pancreatic cancer remains one of the most unfavorable tumor pathologies, characterized by pronounced difficulties in diagnostics and treatment, a significant impact on the ability to work and quality of life of patients, and low indicators of patient life expectancy. Features of the development of malignant neoplasms of this localization contribute to limiting the possibility of performing radical surgery, and therefore a special role in the treatment of patients with pancreatic cancer is assigned to chemotherapy. Specific systemic drug therapy for this pathology is the most important and, in the majority of cases, mandatory element of treatment. It can be carried out in a neoadjuvant, adjuvant and independent mode, include mono- or multi- component schemes, and be combined with other types of systemic or local antitumor effects. The choice of chemotherapy regimen depends primarily on the General somatic status of the patient and is determined by the potential toxicity of a particular combination of cytostatics. This review of the literature demonstrates the effectiveness of various chemotherapy regimens in patients with stage III–IV pancreatic cancer in the first and second lines, describes the frequency of adverse reactions to treatment and their nature, and mentions ways to reduce the toxicity of multicomponent drug therapy regimens. This review is based on the analysis of scientific sources of the Internet resource "National Center for Biotechnological Information".https://www.rpmj.ru/rpmj/article/view/637locally advanced and metastatic pancreatic canceradenocarcinomapalliative cancer carechemotherapydrug therapyoncology
spellingShingle L. I. Moskvicheva
L. V. Bolotina
Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
Исследования и практика в медицине
locally advanced and metastatic pancreatic cancer
adenocarcinoma
palliative cancer care
chemotherapy
drug therapy
oncology
title Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
title_full Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
title_fullStr Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
title_full_unstemmed Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
title_short Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
title_sort possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer
topic locally advanced and metastatic pancreatic cancer
adenocarcinoma
palliative cancer care
chemotherapy
drug therapy
oncology
url https://www.rpmj.ru/rpmj/article/view/637
work_keys_str_mv AT limoskvicheva possibilitiesofpalliativechemotherapyinpatientswithlocallyadvancedandmetastaticpancreaticcancer
AT lvbolotina possibilitiesofpalliativechemotherapyinpatientswithlocallyadvancedandmetastaticpancreaticcancer